• Skip to main content
  • Skip to primary sidebar
Pediatric Pulmonology: The Remaining Barriers to Normalcy in Cystic Fibrosis

The Remaining Barriers to Normalcy in Cystic Fibrosis

  • Issues
  • Resources
  • About
  • Contact
  • Search

Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection

By Lindsay J. Caverly MD; Jiangchao Zhao PhD; John J. LiPuma MD

The importance of infection in the pathogenesis of cystic fibrosis (CF) lung disease has been long recognized, and the use of antibiotics targeting bacteria identified in cultures of respiratory specimens has played a critical role in improving outcomes for individuals with CF. Over the past ∼15 years, the use of culture‐independent methods to assess airway microbiology in CF has revealed complex and dynamic CF airway bacterial communities. Recent areas of investigation of the CF lung microbiome have included exploring how bacterial community structures change over time, particularly with respect to disease progression or pulmonary exacerbation, and in response to antibiotic therapies. This review will discuss what has been learned from these studies as well as how these findings offer opportunities to further refine management of CF airway infection. Pediatr Pulmonol. 2015; 50:S31–S38. © 2015 Wiley Periodicals, Inc.

Read the Full Article  

Journal Issue: The Remaining Barriers to Normalcy in Cystic Fibrosis I

Primary Sidebar

PP Cover - November 2018

Pediatric Pulmonology

The Remaining Barriers to Normalcy in Cystic Fibrosis I

October 2015 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis II

October 2016 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis III

November 2017 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis IV

November 2018 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis V

November 2019 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VI

February 2021 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VII

February 2022 · View Articles

Most Viewed Articles

  • Rapid therapeutic advances in CFTR modulator science

  • Reevaluating approaches to cystic fibrosis pulmonary exacerbations

  • Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

  • Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

  • Inflammation in cystic fibrosis: An update

Quiz and Survey

Test your knowledge and help shape future editions of "The Remaining Barriers to Normalcy." Participate in our Quiz and Survey »

This website is made possible by an educational grant from Vertex Pharmaceuticals Incorporated.

Vertex

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
The content on this site is intended for health professionals.
Wiley